Compare Novartis AG (NVS) vs 10X Genomics Inc (TXG) Price & Performance

Novartis AGTrade

10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs 10X Genomics Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Novartis AG is far larger — about 53× 10X Genomics Inc's market cap, and Novartis AG pays a 3.17% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

	NVS	TXG
Market Cap	$290.25B	$5.48B
Sector	Health	Health
52-Week High	$168.62	$45.80
52-Week Low	$113.50	$11.34
Enterprise Value	$330.27B	$5.02B
Dividend Yield	3.17%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

TXG

New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.